Get the latest news on melanoma
03/06/2018
Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
12/20/2017
FDA Approves Adjuvant Opdivo for Melanoma Treatment
01/18/2018
Adjuvant Pembrolizumab Improves RFS in Melanoma
12/20/2017
FDA Approves Adjuvant Opdivo for Melanoma Treatment
12/19/2017
Melanoma Nursing Initiative Launches to Support Early Recognition and Management of Side Effects From Immunotherapy and Targeted Therapies
10/18/2017
Timing of Melanoma Diagnosis, Treatment Critical to Survival
10/06/2017
Amgen’s Imlygic doubles response rate when added to checkpoint therapy
09/11/2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
07/24/2017
FDA Approves Ipilimumab for Pediatric Melanoma
07/07/2017
Cancer Breakthrough: Personalized Melanoma Vaccines ‘Safe and Effective’ in First Human Clinical Trials
07/05/2017
Some Respond to Nivolumab After Melanoma Progression
06/29/2017
Study Raises Concern Over Accuracy of Melanoma Diagnoses
06/09/2017
Tanning Bed Use Declining Among U.S. Adults
06/09/2017